Medical Moment: Immunotherapy targets brain cancer

Researchers are looking at ways to make a person's own body attack glioblastomas.
Published: Apr. 17, 2024 at 5:41 PM EDT
Email This Link
Share on Pinterest
Share on LinkedIn

(WNDU) - Glioblastoma is the most common and aggressive form of brain tumor.

More than 14,000 people will be diagnosed with one this year. And once diagnosed, most people will not live more than two years.

Despite their aggressive nature, treatments have basically remained the same since 2005. But now, researchers are looking at ways to make a person’s own body attack the tumor.

“My hand, my finger, two fingers got numb,” said Fran Noonan.

Those were the first signs that something was wrong with Noonan. Not long after, she was diagnosed with a glioblastoma.

“They gave me anywhere from six months to 14 months to live,” she said.

The standard of care for these types of brain tumors hasn’t changed in almost 20 years — odds of long-term survival are slim.

“It’s about a 100% recurrence rate, and it usually occurs around the nine-month mark,” said Dr. Dominique Higgins, neurosurgical oncologist at the University of North Carolina.

Now, a team at the University of North Carolina in Chapel Hill is hoping to turn the patient’s own immune system against the tumors.

“It’s an interesting approach to, essentially, a personalized tumor vaccine,” Dr. Higgins said.

Patients undergo brain surgery to remove as much of the tumor as possible. Then, scientists take tumor cells, kill them, and put them in special chambers that contain nucleotides that help to turn on an immune response. Doctors then insert the dime-sized chambers just under the skin in the abdomen.

“And so, they’re basically like little traps for the irradiated tumor cells that are stimulating an immune response,” Dr. Higgins said.

Two days later, the chambers are removed.

“But now, the immune cells in the body know what a tumor looks like, and they can go on and attack it in the brain,” Dr. Higgins said.

Killing the cancer cells and giving patients new hope they’ll win their battle against glioblastoma.

The phase II clinical trial is still enrolling patients with newly diagnosed glioblastomas. Researchers hope that this technique will not only be used to battle glioblastomas, but other cancers — especially ovarian cancer.